Europe needs to refocus its drug anti-counterfeiting measures
This article was originally published in Scrip
Executive Summary
Counterfeit medicines have been big news in Europe over the past two months. The pharmaceutical industry, the World Health Organization and the European Parliament have been vociferously expounding on the success and progress of various initiatives aimed at preventing the emergence of fake medicinal products in the legitimate supply chain. These are welcome and laudable actions, aimed at protecting human health, but are they focusing on the right target?
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.